SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending as the stock approaches double digits, fueled by optimism around a new CEO and potential gamma squeeze, leading to a surge in volume and retail investor enthusiasm. The community is debating short squeeze potential, with some targeting significantly higher prices and urging others to hold. The stock is also being compared to other potential turnaround stories.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community members actively discussing a potential breakout above the $360 resistance level and whether this rally has legs. The conversation includes debates on the long-term potential given competition in EVs and autonomous driving, as well as speculation around Elon Musk's influence and potential catalysts like Optimus robots.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation around a potential acquisition bid from Paramount Skydance, fueling a surge in trading volume and a jump in share price. Community discussions revolve around the potential buyout price, with some anticipating a bidding war, while others are wary of a possible pump and dump. The broader context includes commentary around the streaming sector, debt levels, and the potential impact of Larry Ellison's involvement.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix ($NFLX) is trending with community discussions split between bullish and bearish sentiments. Key catalysts include potential competition from Paramount ($PSKY) and Warner Bros ($WBD), as well as the departure of Netflix's Chief Product Officer. Traders are also closely watching technical levels, with some anticipating a breakout while others foresee a potential pullback.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending due to upcoming earnings, with community members debating whether it will follow the pattern of previous post-earnings drops, or if AI-related news will drive a positive surprise like Oracle or SNPS. The conversation is focused on option pricing, potential volatility, and whether the stock is currently over or undervalued given competition from AI platforms and historical performance. Some traders are anticipating a significant move and weighing bullish vs bearish positions, while others cite a clear downtrend and potential for further declines.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as traders discuss potential buyouts and short squeezes, fueled by optimism surrounding its drug Belapectin and recent institutional buying. Community members are focused on the possibility of a buyout before year-end, with some eyeing triple-digit gains, while others debate the impact of potential FDA actions and ongoing short positions. The stock's price movement and low float are contributing to speculation about an impending squeeze, with retail investors expressing strong bullish sentiment.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid community discussion surrounding the shooting of Charlie Kirk, a conservative political activist, with speculation and accusations flying across the political spectrum.  Some users are focusing on potential motives and connections to ongoing controversies, while others are using the event to fuel partisan arguments.  The stock's volatility and its close association with political sentiment continue to drive interest.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies ($RKT) is trending as chatter revolves around potential short squeeze fueled by high short interest and anticipation of future interest rate cuts. Community members are actively discussing technical indicators, potential price targets, and the impact of the Mr. Cooper merger. The stock's movement is also being tied to broader economic data and potential shifts in Federal Reserve policy.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending downwards, with community members discussing a potential court case and its possible ramifications. Some traders are pointing to technical indicators and expressing bearish sentiment, while others remain optimistic about the company's long-term prospects, citing recent orders and potential catalysts like increased production.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid reports of preparing a majority-cash bid for Warner Bros. Discovery ($WBD), backed by Larry Ellison. The community is actively discussing the potential merger's impact on the streaming landscape and whether Ellison will leverage Oracle ($ORCL) to support the deal. Some investors believe a combined Paramount-Warner could challenge Netflix ($NFLX), while others question the financial feasibility and debt implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ardelyx Inc. (ARDX) jumped 16% higher on Tuesday morning after multiple brokerages upped their price targets on the stock following an upbeat second-quarter earnings report and management changes.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around ARDX jumped 1738% over the past 24 hours, as of Tuesday morning.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_05_at_10_56_25_AM_png_178eba0feb.webp" alt="ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user heaped praises on the management.<stembedurl>https://stocktwits.com/hpf6637/message/623772356</stembedurl>Another user expressed hopes for further price target increases into the high teens.<stembedurl>https://stocktwits.com/Paul_Volcker/message/623769111</stembedurl>Ardelyx on Monday announced changes to its executive leadership team, including the appointment of Edward Conner as Chief Medical Officer and the exit of CFO Justin Renz. The appointments came on the heels of the company reporting $97.7 million in total revenue, reflecting 33% growth year-over-year, and above an analyst estimate of $81.08 million.Ibsrela, the company’s prescription medicine used in adults to treat irritable bowel syndrome with constipation, generated its highest-ever net sales revenue of $65 million in the quarter. Meanwhile, Xphozah, a prescription medicine used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy, brought in $25 million in the quarter.The company also raised its Ibsrela net sales revenue expectations to $250 million to $260 million for the full year 2025. Net loss per share came in at $0.08, compared to a loss of $0.07 per share reported in the corresponding quarter of 2024, but below a loss per share of $0.14 expected by analysts.Multiple analysts subsequently hiked their price target on the stock on Tuesday morning. Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares. The firm noted that Ardelyx posted a solid performance in Q2, driven by Ibsrela strength.Raymond James, meanwhile, raised the firm's price target on Ardelyx to $12 from $11 and kept an ‘Outperform’ rating on the shares. ARDX stock is up by 1% this year but down by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholders-reportedly-sue-ev-giant-ceo-elon-musk-over-robotaxi-claims/chrLMCtRd21">Tesla Shareholders Reportedly Sue EV Giant, CEO Elon Musk Over Robotaxi Claims: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.

Equity

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.


Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Ardelyx, Inc. (ARDX) traded 22% lower on Friday afternoon after Citi lowered its price target on the stock following its recent first-quarter earnings report.Citi reduced its price target on Ardelyx to $10 from $11 while keeping a ‘Buy’ rating. The new price target, however, represents an 83% upside to the stock’s closing price on Thursday.Raymond James also downgraded Ardelyx to ‘Outperform’ from ‘Strong Buy’, and slashed its price target to $11 from $13.The firm said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises.Despite the downgrade, Raymond James remains bullish on Ardelyx, citing its strong execution track record.Ardelyx <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-first-quarter-2025-financial-results-and">reported</a> Q1 total revenue of $74.1 million on Thursday, marking &nbsp;61% growth year-over-year and reflecting increased net product sales and licensing revenue. However, as per Finchat data, this was below an analyst estimate of $79.44 million.U.S. net product sales revenue of Ibsrela, the company’s prescription medication for treating Irritable Bowel Syndrome with Constipation, was $44.4 million, compared to $28.4 million during the same period of 2024.The U.S. net product sales revenue of Xphozah, used as an add-on therapy to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $23.4 million, compared to $15.2 million during the same period in 2024.Net loss per share for the quarter was $0.17, compared to a loss of $0.11 per share in the same quarter of 2024, and broader than an estimated loss of $0.07.On Stocktwits, retail sentiment around ARDX remained in the ‘extremely bullish’ territory over the past 24 hours while message volume rose to ‘extremely high’ from ‘high’.<figure class="image"><img style="aspect-ratio:626/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_02_at_1_56_59_PM_png_99a9fe03a2.webp" alt="ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits" width="626" height="59"><figcaption>ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> is down by over 17% this year and nearly 38% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-core-brand-group-operating-profit-drops-q1/chLUkWFRb0z">Volkswagen Core Brand Group Operating Profit Drops In Q1: But Retail’s Not Rattled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ardelyx Stock Gets Multiple Price Target Cuts After Disappointing Q1 Earnings: But Retail’s Optimistic

Raymond James said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises. 

Shares of biopharma company Ardelyx, Inc. (ARDX) edged up about 0.5% in after-hours trading on Thursday after closing lower during the regular session as investors processed its quarterly earnings and drug sales projections.Ardelyx swung to a fourth-quarter (Q4) net income of $0.02 per diluted share from a loss of $0.12 a year earlier, surpassing analyst expectations of breakeven.&nbsp;Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.Total revenue for the year ended Dec. 31, 2024, was $333.6 million, compared to $124.5 million a year earlier.Ibsrela, its treatment for irritable bowel syndrome with constipation, generated $53.8 million in Q4 net product sales revenue, reflecting about 32% growth from Q3.&nbsp;Full-year 2024 sales reached $158.3 million, and the company expects U.S. net product sales for 2025 to range between $240 million and $250 million.&nbsp;Ardelyx projects Ibsrela to achieve over 10% market share at peak and exceed $1 billion in annual U.S. revenue before its patent expires in 2029.Xphozah, used to manage serum phosphorus levels in adults with chronic kidney disease on dialysis, recorded $57.2 million in Q4 net product sales.In 2024, Xphozah's first full year of commercialization saw U.S. sales hit $160.9 million. The company estimates that peak annual U.S. sales will reach $750 million before its patent expires.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARDX_sentiment_and_message_volume_Feb_20_c5531a04cb.png" alt="ARDX sentiment and message volume Feb 20.png">On Stocktwits, sentiment for ARDX surged deeper into the 'extremely bullish' zone, with message volume spiking 240% in 24 hours.&nbsp;One user highlighted IBSRELA's trajectory toward blockbuster drug status, while another reinforced faith in the company's fundamentals.<stembedurl>https://stocktwits.com/Food4Thought/message/605066169</stembedurl><stembedurl>https://stocktwits.com/Newtothis321/message/604963175</stembedurl>Ardelyx ended 2024 with $250.1 million in cash, cash equivalents, and short-term investments, up from $184.3 million a year earlier.&nbsp;The stock has gained over 13% year-to-date, though short interest has increased from 10% at the start of 2025 to about 11.2% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

Ardelyx Beats Q3 Sales Estimates, Shares Climb

Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:
read more...

Ardelyx's Earnings Outlook

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (Ardelyx or the Company) (NASDAQ: ARDX) and reminds investors of the October 15...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with $OPEN stock after the major announcements last night?

Stocktwits

 stock after the major announcements last night?

Current Price	$6.69
Prev Close	$6.64
Open	$6.61
Dividend Yield	0.00%
50-Day Moving Average	$5.23
Beta	1.01
Avg. Volume	4.45M
PE Ratio	-28.10

52-Week High	$7.18
52-Week Low	$3.21
Market Capitalization	$1.6B
EPS (Annual)	-$0.1664
Price to Book	11.46
Revenue Per Employee	$844,594.94
Enterprise Value/EBITDA	N/A

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News

ARDX Ardelyx Inc